HomeUTHR • BMV
add
United Therapeutics Corp
Previous close
$8,062.17
Year range
$5,672.39 - $8,085.00
Market cap
22.08B USD
Avg Volume
1.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 790.20M | 7.38% |
Operating expense | 354.00M | 18.75% |
Net income | 364.30M | 20.91% |
Net profit margin | 46.10 | 12.60% |
Earnings per share | 7.70 | 24.39% |
EBITDA | 355.60M | -6.81% |
Effective tax rate | 17.95% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.92B | -10.61% |
Total assets | 7.88B | 7.01% |
Total liabilities | 783.80M | -14.80% |
Total equity | 7.10B | — |
Shares outstanding | 43.83M | — |
Price to book | 49.58 | — |
Return on assets | 10.92% | — |
Return on capital | 12.16% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 364.30M | 20.91% |
Cash from operations | 346.20M | 1.47% |
Cash from investing | -227.60M | -84.74% |
Cash from financing | 98.40M | 231.73% |
Net change in cash | 217.00M | 51.43% |
Free cash flow | -94.24M | -145.56% |
About
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
Founded
1996
Headquarters
Website
Employees
1,400
